NovaBridge Biosciences (NBP) Return on Sales (2019 - 2023)

NovaBridge Biosciences (NBP) posted quarterly Return on Sales of 0.3% for Q4 2023, down 62.52% on a QoQ basis from 0.79% in Q3 2023.

NovaBridge Biosciences (NBP) Return on Sales (2019 - 2023) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Return on Sales for 3 consecutive years, with 0.3% the latest figure, recorded in Q4 2023.

Quarterly Return on Sales changed N/A year-over-year to 0.3% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.3% (changed N/A YoY) and the FY2023 annual result came in at 1.99%, down 50.0% from the prior year.
Return on Sales retreated to 0.3% in Q4 2023 per NBP's latest filing, from 0.79% in the prior quarter.
Over the last five years, Return on Sales for NBP reached as high as 2.13% in Q2 2023 and fell as low as 0.16% in Q3 2019.
A 3-year average of 0.73% and a median of 0.6% in 2020 frame the typical range for Return on Sales.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	0.00%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	NovaBridge Biosciences	389.86 Mn	389.86 Mn	-	-

Download Data